Research
Micronutrients & recovery
Orlistat improves cardiovascular risk factors, including reducing the incidence of type 2 diabetes and improving lipid profiles, despite causing gastrointestinal side effects.
Orlistat not only aids weight loss but also significantly reduces the risk of developing type 2 diabetes in obese individuals with impaired glucose tolerance. It also improves cholesterol and blood pressure. However, users must manage gastrointestinal side effects, which are common but not necessarily dangerous.
GoodSupportsHIGH confidence
Orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and low density lipoprotein cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered concentrations of high density lipoprotein.
Why this rating
Based on subgroup analyses within the meta-analysis, including a large 4-year trial (XENDOS).
Source
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker et al. · BMJ · 2007
Meta-analysis · 30 studiesCited 799×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →